VaxInnate keeps slowly raising capital for seasonal flu vaccine
VaxInnate, a New Jersey startup, has raised more equity - on top of $53 million in government contracts - to develop a seasonal and pandemic flu vaccine.
VaxInnate, a New Jersey startup, has raised more equity - on top of $53 million in government contracts - to develop a seasonal and pandemic flu vaccine.
New Jersey’s VaxInnate is developing inoculations to ward off seasonal and pandemic flu, dengue fever and Clostridium difficile. The well-capitalized company has raised a recent round of $6 million, according to a regulatory filing. The company genetically fuses vaccine antigens to flagellin, a protein that forms the flagella of a bacterium that’s known for being highly […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The former head of Sanofi’s (NYSE:SNY) vaccines division, one of the largest vaccine companies in the world, has joined a biotechnology company developing infectious disease vaccines as its CEO. Wayne Pisano will lead Cranbury, New Jersey-based VaxInnate, a biotechnology company founded by two Yale School of Medicine immunobiology professors in 2002 — Ruslan Medzhitov and […]